Blog

A wooden abacus with black and white beads sits on a green table. The abacus is old and has a vintage feel to it

The HealthTech M&amp;A market in October 2025 is defined by a "flight to quality" and a bifurcation of valuations, with premiums overwhelmingly concentrated in AI-driven and strategically aligned assets. M&amp;A activity is steady, driven by significant private equity "dry powder" and strategic buyers seeking efficiency gains and proprietary technology.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>Current M&amp;A Valuation Multiples (Q4 2025)The general average multiples are misleading due to the massive premium paid for high-growth, high-margin, and highly defensible assets.EV/Revenue &gt; 4.0x – 6.0x (Average of Q1 2025: 4.8x)EV/EBITDA &gt; 10.0x – 14.0x (For profitable companies)Key Trends Driving Multiples1. AI Integration &amp; Innovation &gt; Highest Premium (6x-8x+ Revenue)Buyers are paying a premium for proprietary AI algorithms (especially in diagnostics and predictive analytics) that demonstrate proven clinical validation and potential for significant cost reduction2. Shift to Value-Based Care (VBC) &nbsp;&gt; Premium (5.5x – 7.0x Revenue)Solutions enabling the VBC shift (e.g., remote monitoring, population health analytics) are highly valued because they deliver measurable cost savings and improved patient outcomes, a top priority for payers and providers.3. Recurring Revenue &amp; Scalability &gt; Premium Tied to ARR (6x – 20x ARR)Like general SaaS companies, HealthTech with high Annual Recurring Revenue (ARR), strong growth trajectories, and high gross margins are favored. Recurring revenue is seen as highly defensible.4. "Flight to Quality" &gt; Concentration of CapitalInvestors are shifting away from aggressive expansion toward a "selective scale" model, favoring later-stage companies with established revenue, clear paths to profitability, and a low Customer Acquisition Cost (CAC).Key Variables Driving Valuations The difference between a company valued at 4.0x revenue and one at 8.0x is determined by several core variables:1. Defensibility and Intellectual Property (IP) Proprietary Technology: The presence of unique IP, patents, or proprietary datasets that create a strong competitive moat is a major value-driver. "Workflow Lock-in": Solutions that are deeply integrated into existing clinical or administrative workflows (e.g., EHR systems) create high switching costs for buyers, significantly boosting valuation. 2. Financial Quality Gross Margin: Companies with high gross margins are valued at a premium, as they indicate greater pricing power and efficient service delivery (especially prevalent in software-only solutions). Profitability/Path to Profitability: In the current climate, proven profitability (reflected in the $10.0x–14.0x EV/EBITDA range) is a baseline requirement for premium valuations. Unprofitable firms must present a credible, near-term path to positive earnings. 3. Regulatory Clarity (EU AI Act &amp; EHDS) The European regulatory landscape is becoming a critical value driver:EU AI Act Compliance: The implementation of the EU AI Act (with compliance rules applicable starting from early 2025) places most healthcare AI tools into the "high-risk" category. Companies that have proactively achieved or demonstrated a clear plan for compliance with the Act's data governance, documentation, and human oversight requirements are seen as lower risk and command higher multiples. European Health Data Space (EHDS): Companies whose technology is positioned to leverage the EHDS—facilitating safe, compliant cross-border data exchange—gain a strategic advantage in developing and training robust AI models. 4. Buyer Dynamics Private Equity (PE): PE firms continue to pay a structural premium, offering a median EV/EBITDA multiple of approximately 11.2x in Europe for desirable, scalable assets, largely due to capital deployment pressure and financial structuring. Strategic (Corporate) Buyers: Large Pharma, MedTech, and Hospital systems are driving M&amp;A primarily through a "string-of-pearls" consolidation strategy to acquire specific capabilities (like AI diagnostics or advanced analytics), even if at a lower median multiple (~8.5x EV/EBITDA) than PE, as they account for expected internal synergies.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

HealthTech M&A Multiples October 2025: Current Trends and Variables driving valuations

Nelson Advisors will be speaking, presenting and chairing a number of panels at HealthTech conferences and events across the UK, Europe and Middle East in the run up to Christmas, please feel free to meet us in person, come and say hello :)&nbsp;October 2025Healthcare Summit 2025, London, UK – Chairing the HealthTech M&amp;A Panel<a data-mce-href="https://healthcare-summit.co.uk" href="https://healthcare-summit.co.uk" title="https://healthcare-summit.co.uk" target="_blank" rel="noopener">https://healthcare-summit.co.uk</a>Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel<a data-mce-href="https://healthcare-summit.co.uk" href="https://healthcare-summit.co.uk" title="https://healthcare-summit.co.uk" target="_blank" rel="noopener">https://healthcare-summit.co.uk</a>NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland – Attending the NHS Innovation Accelerator sessions<a data-mce-href="https://nhscepcommunity.com/events/179287" href="https://nhscepcommunity.com/events/179287" title="https://nhscepcommunity.com/events/179287" target="_blank" rel="noopener">https://nhscepcommunity.com/events/179287</a>Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&amp;A Panel<a data-mce-href="https://www.globalhealthsaudi.com/en/home.html" href="https://www.globalhealthsaudi.com/en/home.html" title="https://www.globalhealthsaudi.com/en/home.html" target="_blank" rel="noopener">https://www.globalhealthsaudi.com/en/home.html</a>November 2025HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel<a data-mce-href="https://impactx2050.com/healthtechx" href="https://impactx2050.com/healthtechx" title="https://impactx2050.com/healthtechx" target="_blank" rel="noopener">https://impactx2050.com/healthtechx</a>MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates &amp; Hospitals: How to Build Meaningful MedTech Partnerships" panel<a data-mce-href="https://med-tech.world/malta" href="https://med-tech.world/malta" title="https://med-tech.world/malta" target="_blank" rel="noopener">https://med-tech.world/malta</a>MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards<a data-mce-href="https://med-tech.world/malta" href="https://med-tech.world/malta" title="https://med-tech.world/malta" target="_blank" rel="noopener">https://med-tech.world/malta</a>Leaders in Health Summit 2025<a data-mce-href="https://wellfounded.health/leadersinhealth" href="https://wellfounded.health/leadersinhealth" title="https://wellfounded.health/leadersinhealth#" target="_blank" rel="noopener">https://wellfounded.health/leadersinhealth#</a>December 2025HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack: Emerging Vulnerabilities in Healthcare”Panel<a data-mce-href="https://healthtechforward.com" href="https://healthtechforward.com" title="https://healthtechforward.com" target="_blank" rel="noopener">https://healthtechforward.com</a>Healthcare Club, IESE Business School, Barcelona, Spain<a data-mce-href="https://www.iese.edu" href="https://www.iese.edu" title="https://www.iese.edu" target="_blank" rel="noopener">https://www.iese.edu</a>HealthInvestor Power List Awards 2025, London, UK – Judging Panel<a data-mce-href="https://healthinvestorpowerlist.com" href="https://healthinvestorpowerlist.com" title="https://healthinvestorpowerlist.com" target="_blank" rel="noopener">https://healthinvestorpowerlist.com</a>________________________________________________________Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.ukFounders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk#NelsonAdvisors&nbsp;#MedTech&nbsp;#HealthTech&nbsp;#DigitalHealth&nbsp;#HealthIT&nbsp;#Cybersecurity&nbsp;#HealthcareAI&nbsp;#ConsumerHealthTech&nbsp;#Mergers&nbsp;#Acquisitions&nbsp;#Partnerships&nbsp;#Growth&nbsp;#Strategy&nbsp;#NHS&nbsp;#UK&nbsp;#Europe&nbsp;#USA&nbsp;#VentureCapital&nbsp;#PrivateEquity&nbsp;#Founders&nbsp;#BuySide#SellSideNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTContact Us<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a><a data-mce-href="mailto:paul@nelsonadvisors.co.uk" href="mailto:paul@nelsonadvisors.co.uk" title="paul@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">paul@nelsonadvisors.co.uk</a>

Nelson Advisors MedTech and HealthTech events: Q4 2025

The Biopsychosociotechnical (BPST) model is a systems-based framework for health improvement that extends the traditional Biopsychosocial (BPS) model by incorporating the role of technology. In HealthTech, this model is a key framework to watch in 2026 as it advocates for a more holistic, human centered and practical approach to designing and implementing healthcare technologies.The BPST model views health and its determinants as a complex adaptive system of systems involving the interaction of four major domains:Biological (bio−): Genetics, physical health, disease pathology, physiological function. Psychological (psycho−): Thoughts, emotions, behaviors, coping mechanisms, mental health. Social (social−): Socioeconomic factors, culture, support networks, community and social determinants of health. Technical (techno−): The tools, technology, tasks, environments and organisational processes (eg. Electronic Health Records (EHRs), mobile health apps, AI, remote monitoring devices). &nbsp; Relevance in Healthtech for 2026 The BPST model provides a "practical theory" for health improvement, making it highly relevant as digital health technologies become more integrated and complex.1. Human-Centered Design and Implementation The model calls for a participatory design process that ensures technology is not just medically sound, but also psychologically and socially supportive.Focus: Designing health technologies that seamlessly integrate into the patient's real-world social context and address potential psychological barriers (eg. anxiety, stigma, digital literacy). 2026 Trend: A push toward personalised digital health products and platforms where the technical solution is tailored to the individual's specific biological, psychological and social circumstances. 2. Addressing Health Disparities By explicitly including the social and techno components, the BPST model forces a consideration of how technology can reduce or inadvertently worsen health inequalities.Focus: Designing and implementing technology to be accessible and effective across diverse populations, acknowledging differences in digital access, cultural beliefs and socioeconomic status. 2026 Trend: The use of technology to support inclusion health groups and address social determinants of health, ensuring that AI-driven diagnostics and remote care are equitable. 3. Systemic Intervention Management The model moves beyond simple "treatments" to focus on systems-focused interventions that modify the entire BPST context.Focus: Utilising technology to create holistic, continuous-care systems rather than isolated solutions. For example, remote patient monitoring (techno−) needs to be integrated with care coordination (social−) and psychological support (psycho−) to manage a chronic biological condition (bio−). 2026 Trend: Growing focus on Intervention Management to support the full lifecycle of health improvement, including continuous monitoring, feedback loops, and dynamic adjustments based on real-world system data. In short, the BPST model serves as the theoretical underpinning for the next generation of health technologies that must function as interconnected components within a patient's entire life and healthcare ecosystem, not just as isolated medical tools.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Biopsychosociotechnical (BPST) Models: One to Watch in HealthTech 2026

The National Health Service (NHS) is currently undergoing a fundamental transformation, mandated by the government’s 10 Year Health Plan, which prioritises the shift from analogue to digital operations. This strategic commitment frames AI adoption not merely as an efficiency measure, but as a critical requirement for securing the NHS’s future financial sustainability. Key objectives of this ambitious plan include moving "from bricks to clicks" and granting patients control over a single, secure and authoritative account of their health data, a unified patient record, which facilitates more coordinated, personalised, and predictive care models. &nbsp;&nbsp; Crucially, the government has established a mechanism to enforce continuous digital investment, requiring all NHS organisations, for the first time, to reserve a minimum of 3% of their annual expenditure specifically for one-time investments in service transformation. This policy is designed to overcome historical underinvestment in technology and accelerate the translation of proven innovations, such as the AI trial results, into national practice. This mandated capital expenditure mechanism ensures that the necessary financial foundation exists to integrate large-scale digital tools like Microsoft 365 Copilot, providing a sustained route away from dependence on archaic or legacy IT systems. The modernisation effort is thus inextricably linked to structural fiscal sustainability.The adoption of AI productivity tools is directly motivated by the significant administrative burden placed upon NHS staff. Health innovation leadership, including clinicians, recognises the deep frustration caused by "archaic technology that makes day-to-day tasks painstakingly long". The core mandate of the Microsoft 365 Copilot trial was explicitly to target this administrative friction, thereby freeing up staff "to focus on what they want to be doing - treating patients". &nbsp;&nbsp; The highly successful initial adoption of M365 Copilot is predominantly anchored in its application to generic "knowledge-worker tasks" across the organisation. These tasks include high-volume, non-clinical documentation such as handling Freedom of Information requests, documenting critical incidents, and automating Human Resources inquiries. This strategic focus on reducing friction in non-clinical documentation minimises exposure to immediate clinical risk, establishing M365 Copilot as an optimal, low-risk, first-wave model for large-scale generative AI deployment within the NHS.Source: <a data-mce-href="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" href="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" title="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path</a>

Strategic Analysis of the NHS and Microsoft 365 Copilot Trial

The Regulatory Vanguard: Assessing the MHRA AI Airlock and the UK’s Potential for Leadership in Ambient Voice Technology Governance &nbsp;&nbsp; Strategic Context: The UK’s Principles-Based Approach to AIaMD Regulation &nbsp;&nbsp; The governance of Artificial Intelligence as a Medical Device (AIaMD) presents unique challenges related to algorithmic adaptivity, transparency, and assurance of continuous safety. The UK’s regulatory approach to this domain is strategically defined by a commitment to agility and innovation, leveraging existing sectoral regulators rather than relying on monolithic, preemptive legislation. &nbsp;&nbsp; The Policy Divergence: Agility vs. Prescription in Global AI Governance &nbsp;&nbsp; The foundation of the UK’s ambition is laid out in its National AI Strategy, which aims to establish the country as a "global AI superpower" by fostering "the most trusted and pro-innovation governance framework". This philosophical stance emphasises a context-sensitive, iterative approach that allows for adaptation by specialised regulators, such as the Medicines and Healthcare products Regulatory Agency (MHRA). This model deliberately contrasts with the comprehensive and prescriptive legislative approaches adopted in other major jurisdictions, notably the European Union’s AI Act. The strategic decision is driven by a mandate to avoid introducing "new rigid and onerous legislative requirements" that could potentially impede the rapid advancement of AI innovation. &nbsp;&nbsp; The UK framework rests on five cross-sectoral principles, intended to guide the development and deployment of AI systems across all regulated industries: safety, security and robustness; appropriate transparency and explainability; fairness; accountability and governance; and contestability and redress. By delegating the interpretation and operationalisation of these high-level principles to expert sectoral bodies, the UK hopes to maintain greater flexibility in managing sector-specific risks. &nbsp;&nbsp; This decentralised, principles-based model, however, carries an inherent structural tension. While it grants high operational flexibility, it simultaneously shifts the burden of interpreting these broad principles into concrete, technical compliance requirements onto the regulated manufacturers. This regulatory uncertainty can, in the initial stages, introduce friction for developers seeking market authorization. The central mechanism designed to mitigate this risk, translating conceptual principles (like Fairness and Accountability) into empirical, sector-specific technical requirements (such as validation protocols for specific datasets or robust post-market surveillance methods) is the MHRA’s AI Airlock. The Airlock thus functions as the essential, agile bridge between high-level policy ambition and pragmatic regulatory implementation.Source: <a data-mce-href="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" href="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" title="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi</a>

MHRA AI Airlock and the UK’s Potential for Leadership in Ambient Voice Technology Governance

The Boston Consulting Group (BCG) report, "Innovation for Impact: Unlocking the Potential of the UK’s Healthcare Ecosystem," highlights the UK's strong foundations in healthcare innovation but notes that this potential is not consistently translated into patient impact and economic value.The report identifies a significant untapped economic and societal opportunity, estimating that by 2030, the healthcare sector's contribution to GDP could be approximately £78 billion greater than current projections (a 76% increase), with further substantial benefits for the NHS and society.Key Findings and ChallengesThe report outlines the UK's strengths and the major barriers to innovation adoption and scaling:Strong Foundations: The UK possesses world-class assets, including a prominent life sciences sector, leading academic institutions, rich health data, and the NHS as a unique national platform. Untapped Potential: Despite these strengths, the translation of innovation into widespread patient benefit and economic growth is hampered.Slow Adoption: The UK lags some European peers in the median time for new medicines to reach patients. Economic Lag: The sector's economic contribution is lower than its potential. Barriers to Innovation:Workforce Capacity: There is a lack of capacity and capabilities for translational research and innovation within the NHS, often due to poorly defined career pathways, limited protected time for innovation, and a gap in digital/AI fluency. Cultural and Process Hurdles: NHS staff often lack the support to test, adopt, and scale innovation, facing a risk-averse culture and disjointed policy and regulation. Scaling Difficulty: While innovative solutions are frequently tested in the NHS, the biggest challenge is the successful scaling and diffusion of proven innovations from early-stage, site-specific adoption to national uptake, often limited by regional variability and disparate funding. Long-Term Strategy: A lack of consistent, long-term strategy with collective accountability and sustained investment over a 3- to 10-year horizon prevents overcoming long-standing barriers. Main Recommendations The BCG report, often aligned with the goals of the NHS's own Innovation Ecosystem Programme, generally proposes a strategic and collaborative approach across the ecosystem to unlock this potential:Prioritise and Align Innovation:Focus Goals: Align the innovation ecosystem with the government's major health and economic goals, focusing on shifts like hospital to community, analogue to digital, and sickness to prevention (e.g., early detection, diagnosis, and personalised medicine). Strategic Investment: Establish co-ordinated oversight and align innovation funding to fund fewer but larger pools of money to support scaling. Make Innovation Core to NHS Business:Workforce Integration: Embed innovation as a core part of NHS roles by developing clearer career pathways, providing protected time for innovation, and enhancing digital and AI literacy within the workforce. Incentives and Monitoring: Develop incentives and monitor delivery using Key Performance Indicators (KPIs) for the testing and adoption of innovation to drive accountability. Simplify and Strengthen Structures:Streamline Governance: Simplify overcomplicated oversight structures to allow innovation programs to flourish at the local level while maintaining national consistency. Data and IP: Strengthen data access and information governance to enable better collaboration across the NHS, academia, and industry, which is crucial for leveraging the UK's rich health data assets, especially for AI and genomic research. Local Mobilisation: Encourage and support local systems to take the lead in co-ordination and decision-making for innovation adoption, promoting flexibility and rapid scaling from proven centres of excellence.Source: <a href="https://www.bcg.com/publications/2025/united-kingdom-innovation-for-impact-unlocking-the-potential-of-the-healthcare-ecosystem">https://www.bcg.com/publications/2025/united-kingdom-innovation-for-impact-unlocking-the-potential-of-the-healthcare-ecosystem</a>

Nelson Advisors

Blog

HealthTech M&A Multiples October 2025: Current Trends and...

Nelson Advisors MedTech and HealthTech events: Q4 2025

Biopsychosociotechnical (BPST) Models: One to Watch in He...

Strategic Analysis of the NHS and Microsoft 365 Copilot T...

MHRA AI Airlock and the UK’s Potential for Leadership in ...

BCG Report - Innovation for Impact: Unlocking the Potenti...